Envoy Medical (COCH) Q4 2024 earnings summary

Executive summary

• Achieved FDA approval to begin pivotal clinical trial for fully implanted Acclaim cochlear implant, with strong patient interest and enrollment progress.

• Advanced legislative and reimbursement efforts, including new CPT codes and progress on the Hearing Device Coverage Clarification Act.

• Continued product development with promising technical improvements and no serious adverse events in early feasibility trials.

Financial highlights

• Net revenues decreased by $91,000 year-over-year, mainly due to lower battery replacement sales from supply chain limitations.

• Cost of goods sold decreased by $47,000, aligned with the revenue decline.

• R&D expenses increased by $1.2 million year-over-year, driven by higher headcount for clinical study preparation.

• Sales and marketing expenses rose by $68,000, primarily from legal and professional fees for insurance reimbursement efforts.

• General and administrative expenses decreased by $438,000, reflecting lower professional service costs post-business combination.

• Net loss for 2024 was $27.97 million, compared to $31.27 million in 2023.

• Cash and cash equivalents at year-end were approximately $5.5 million.

Outlook and guidance

• Enrollment in the pivotal clinical trial for the Acclaim cochlear implant is progressing well, with six of ten planned participants enrolled and implanted.

• Anticipates potential Medicare coverage for Esteem implant if the Hearing Device Coverage Clarification Act passes.

• New CPT codes for fully implanted active middle ear implants effective July 2025 may enhance reimbursement opportunities.